Medtronic steams ahead with carotid stenting trial:
This article was originally published in Clinica
Medtronic has begun the third in a series of studies to evaluate its system of devices to treat blockages in the carotid arteries that can lead to ischaemic strokes. The MAVErIC III clinical trial will gather data for submission to US regulatory authorities to evaluate the safety and efficacy of a combination of the firm's Interceptor PLUS carotid filter system and Exponent self-expanding carotid stent. It has already enrolled the first patient and will include 413 high-risk patients at 35 centres in North America. According to the American Heart Association, carotid stenting is expected to grow from about 17,000 procedures this year to more than 125,000 worldwide in 2008, Medtronic said.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.